Ultravate is a high-potency corticosteroid and is generally avoided on the face because the skin there is thin and more prone to atrophy and steroid-induced rosacea. A dermatologist may prescribe a lower-potency steroid for facial lesions.
Typical short-term therapy lasts up to 2 weeks. Using the entire tube on a limited area within this period is acceptable, but extending treatment beyond the recommended duration increases the risk of side effects and should be discussed with a clinician.
Yes. Ultravate is classified as a prescription-only medicine (POM) by the MHRA and must be dispensed with a valid NHS or private prescription.
Discontinue Ultravate immediately and contact your healthcare provider. Skin atrophy is a sign of excessive steroid exposure and may require an alternative treatment plan.
Occlusion markedly increases drug absorption and the risk of systemic effects. It should only be done under specialist instruction, typically for a very short period and on limited skin areas.
Topical halobetasol can be absorbed systemically in small amounts. While occasional use on a small area is unlikely to affect a breastfed infant, routine or extensive use should be discussed with a health professional to weigh benefits against potential risks.
Concurrent use of multiple corticosteroids can increase the overall steroid load, potentially suppressing the HPA axis. Your prescriber may adjust dosages or monitor cortisol levels to prevent adverse effects.
Avoid using other topical irritants (e.g., retinoids, harsh soaps) on the same area, and refrain from applying it to broken skin, open wounds, or infected lesions unless directed by a clinician.
Use in children under 12 is generally reserved for specialist care. The higher potency raises the risk of systemic absorption and growth suppression, so a pediatric dermatologist should evaluate the need and dosage.
Halobetasol propionate is classified as a super-high-potency (class I) steroid, whereas betamethasone is typically medium to high potency (class II-III). This means Ultravate produces a stronger anti-inflammatory effect but also carries a greater risk of side effects if misused.
Ultravate contains halobetasol propionate as its active component. It belongs to the class of high-potency topical corticosteroids and is supplied in a 30 g tube. In the United Kingdom, Ultravate is a prescription-only medicine (POM) regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). It is intended for short-term treatment of inflammatory skin conditions where a strong anti-inflammatory effect is required.
Halobetasol propionate is a synthetic glucocorticoid. When applied to the skin it:
These actions together diminish redness, itching, and thickness associated with conditions like psoriasis and severe eczema. Because the drug is applied topically, systemic absorption is generally low, but it can increase with extensive use or use over large surface areas.
Ultravate is approved in the UK for the short-term (usually up to 2 weeks) management of:
Treatment is targeted to the affected areas and is not intended for large-area or whole-body use except under specialist supervision.
If any of these occur, discontinue use and seek medical advice promptly.
Topical halobetasol has limited systemic interaction potential. However:
General Advice: Inform your pharmacist of all medicines, supplements, and herbal products you use before starting Ultravate.
This article provides educational information about Ultravate and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
